Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Total Non-Current Liabilities (2016 - 2025)

Abeona Therapeutics (ABEO) has 11 years of Total Non-Current Liabilities data on record, last reported at $37.3 million in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 49.41% year-over-year to $37.3 million; the TTM value through Sep 2025 reached $37.3 million, down 49.41%, while the annual FY2024 figure was $32.9 million, 84.5% up from the prior year.
  • Total Non-Current Liabilities reached $37.3 million in Q3 2025 per ABEO's latest filing, down from $52.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $73.7 million in Q3 2024 and bottomed at $16.9 million in Q3 2023.
  • Average Total Non-Current Liabilities over 5 years is $31.4 million, with a median of $28.2 million recorded in 2021.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 335.51% in 2024, then crashed 49.41% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $28.2 million in 2021, then tumbled by 36.92% to $17.8 million in 2022, then increased by 0.16% to $17.8 million in 2023, then skyrocketed by 84.5% to $32.9 million in 2024, then increased by 13.41% to $37.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $37.3 million in Q3 2025, $52.5 million in Q2 2025, and $33.2 million in Q1 2025.